Hedera Dx, the European techbio company headquartered in Switzerland, today announced the closing of a €15 million Series A financing round to drive advanced cancer care. The round was led by Vsquared Ventures, with Tesi also joining as a new investor alongside significant participation from existing backers Helsana HealthInvest, Eyrir Venture Management, Inventure and Top Harvest. The funding will fuel Hedera Dx’s mission to overcome structural barriers that prevent cancer patients from accessing targeted cancer therapies. The founders have led and scaled some of the most relevant European genetics companies and operations (including Blueprint Genetics, Roche and Molecular Health) and are now focused on building the next global leader in healthcare.
